» Articles » PMID: 12707354

Microsomal Prostaglandin E Synthase-1 is a Major Terminal Synthase That is Selectively Up-regulated During Cyclooxygenase-2-dependent Prostaglandin E2 Production in the Rat Adjuvant-induced Arthritis Model

Overview
Journal J Immunol
Date 2003 Apr 23
PMID 12707354
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

To better define the role of the various prostanoid synthases in the adjuvant-induced arthritis (AIA) model, we have determined the temporal expression of the inducible PGE synthase (mPGES-1), mPGES-2, the cytosolic PGES (cPGES/p23), and prostacyclin synthase, and compared with that of cyclooxygenase-1 (COX-1) and COX-2. The profile of induction of mPGES-1 (50- to 80-fold) in the primary paw was similar to that of COX-2 by both RNA and protein analysis. Quantitative PCR analysis indicated that induction of mPGES-1 at day 15 was within 2-fold that of COX-2. Increased PGES activity was measurable in membrane preparations of inflamed paws, and the activity was inhibitable by MK-886 to >or=90% with a potency similar to that of recombinant rat mPGES-1 (IC(50) = 2.4 microM). The RNA of the newly described mPGES-2 decreased by 2- to 3-fold in primary paws between days 1 and 15 postadjuvant. The cPGES/p23 and COX-1 were induced during AIA, but at much lower levels (2- to 6-fold) than mPGES-1, with the peak of cPGES/p23 expression occurring later than that of COX-2 and PGE(2) production. Prostacyclin (measured as 6-keto-PGF(1alpha)) was transiently elevated on day 1, and prostacyclin synthase was down-regulated at the RNA level after day 3, suggesting a diminished role of prostacyclin during the maintenance of chronic inflammation in the rat AIA. These results show that mPGES-1 is up-regulated throughout the development of AIA and suggest that it plays a major role in the elevated production of PGE(2) in this model.

Citing Articles

Prostanoids and Resolution of Inflammation - Beyond the Lipid-Mediator Class Switch.

Schmid T, Brune B Front Immunol. 2021; 12:714042.

PMID: 34322137 PMC: 8312722. DOI: 10.3389/fimmu.2021.714042.


Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases.

Wang Q, Li Y, Wu M, Huang S, Zhang A, Zhang Y Am J Transl Res. 2021; 13(1):391-419.

PMID: 33527033 PMC: 7847505.


Anti-osteoarthritic Effects of an Herbal Composition LI73014F2 on Interleukin-1β-induced Primary Human Articular Chondrocytes.

Kim H, Lee H, Lee D, Choi B, Yang S Molecules. 2020; 25(9).

PMID: 32349389 PMC: 7249004. DOI: 10.3390/molecules25092033.


Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia.

Mukai M, Uchida K, Takano S, Iwase D, Aikawa J, Inoue G Lipids Health Dis. 2018; 17(1):137.

PMID: 29898737 PMC: 6001124. DOI: 10.1186/s12944-018-0792-7.


Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.

Garscha U, Romp E, Pace S, Rossi A, Temml V, Schuster D Sci Rep. 2017; 7(1):9398.

PMID: 28839250 PMC: 5571211. DOI: 10.1038/s41598-017-09795-w.